Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

University Hospitals of Cleveland, Cleveland, Ohio, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Cleveland, Ohio
Treatments:ChemotherapyHospital:University Hospitals of Cleveland
Drugs:Journal:Link
Date:Dec 2005

Description:

Patients: This Phase II study involved 39 women with inoperable or large operable metastatic breast cancer. The median age was 47 years.

Treatment: The treatment consisted of two chemotherapeutic agents: docetaxel and doxorubicin. Patients thereafter underwent surgery as determined by their physicians.

Toxicity: Grade 3-4 toxicities included neutropenia, mucositis, fatigue, pain, and hand-foot syndrome.

Results: The median overall survival was not reported as 88% of patients survived after 70 months after the start of treatment. The authors concluded, "Primary chemotherapy with dose-dense doxorubicin and docetaxel given sequentially is well tolerated and allows a high rate of breast sparing in patients with large breast cancers."

Support: Aventis Pharmaceuticals financially supported this study. Aventis manufactures and/or markets docetaxel.

Correspondence: Brenda W. Cooper





Back